Newsroom | 11437 results

SHANGHAI e JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK), e Organon (NYSE: OGN) oggi hanno annunciato che la Commissione europea (CE) ha concesso l'autorizzazione all'immissione in commercio di BILDYOS® (denosumab) soluzione iniettabile da 60 mg/ml e BILPREVDA® (denosumab) soluzione iniettabile da 120 mg/1,7 ml, biosimilari rispettivamente di PROLIA (denosumab) e XGEVA (denosumab), per tutte le indicazioni dei prodotti di riferimento.1,2 “Le autorizzazioni di BILD...

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696, HK) en Organon (NYSE: OGN) hebben vandaag aangekondigd dat de Europese Commissie (EC) een handelsvergunning heeft verleend voor BILDYOS® (denosumab)-injectie 60 mg/ml en BILPREVDA® (denosumab)-injectie 120 mg/1,7 ml, biosimilars van respectievelijk PROLIA (denosumab) en XGEVA (denosumab), voor alle indicaties van de referentieproducten.1,2 "De goedkeuringen door de EC van BILDYOS en BILPREVDA markeren een cruci...

SHANGHAI et JERSEY CITY, New Jersey--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) et Organon (NYSE : OGN) ont annoncé aujourd’hui que la Commission européenne (CE) avait accordé une autorisation de mise sur le marché pour BILDYOS® (denosumab) injection 60 mg/mL et BILPREVDA® (denosumab) injection 120 mg/1,7 mL, biosimilaires de PROLIA (denosumab) et XGEVA (denosumab), respectivement, pour toutes les indications des produits de référence.1,2 « Les autorisations de mise sur le marché...

SHANGHAI y JERSEY CITY, Nueva Jersey--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) y Organon (NYSE: OGN) acaban de anunciar que la Comisión Europea (CE) ha autorizado la comercialización de BILDYOS® (denosumab) inyectable 60 mg/ml y BILPREVDA® (denosumab) inyectable 120 mg/1,7 ml, biosimilares de PROLIA (denosumab) y XGEVA (denosumab), respectivamente, para todas las indicaciones de los productos de referencia.1,2 «Las aprobaciones de la CE de BILDYOS y BILPREVDA suponen un hito cr...

SHANGHAI UND JERSEY CITY, NEW JERSEY--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute die Erteilung der Marktzulassung durch die Europäische Kommission (EK) für die BILDYOS® (Denosumab)-Injektion 60 mg/ml und die BILPREVDA® (Denosumab)-Injektion 120 mg/1,7 ml bekannt, Biosimilars zu PROLIA (Denosumab) bzw. XGEVA (Denosumab. Diese Zulassung gilt für alle Indikationen der Referenzprodukte.1,2 „Die Zulassung von BILDYOS und BILPREVDA durch die EK ist e...

CARROLLTON, Ga.--(BUSINESS WIRE)--Tanner Health and Healthliant Ventures are pleased to announce a partnership with Incision USA, a healthcare technology company dedicated to supporting surgical teams with intuitive, clinician-designed tools that foster confidence, well-being and efficiency. With Incision’s Assist and Academy solutions, operating room (OR) staff can confidently prepare for surgical cases by giving them on-demand access to surgeon preferences, team workflows, visual OR setup gui...

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Stereotactic Neuro-Navigation System Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Asia-Pacific stereotactic neuro-navigation system market is projected to reach $702.2 million by 2035 from $170.7 million in 2024, growing at a CAGR of 14.05% during the forecast period 2025-2035. The market for APAC stereotactic neuro-navigation systems is expanding quickly due to the increased prevalence of ne...

DUBLIN--(BUSINESS WIRE)--The "Europe Stereotactic Neuro-Navigation System Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Europe stereotactic neuro-navigation system market is projected to reach $1.01 billion by 2035 from $269.0 million in 2024, growing at a CAGR of 13.14% during the forecast period 2025-2035. The market for stereotactic neuro-navigation systems in Europe is expected to develop significantly due to the rising demand for...

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Robotic Neurosurgery Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Asia-Pacific robotic neurosurgery market is projected to reach $587.0 million in 2035 and estimated $92.6 million in 2025, growing at a CAGR of 20.28% during the forecast period 2025-2035 The increasing popularity of minimally invasive procedures is speeding up adoption even more because they lower surgical risks and recuperati...

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--European Commission Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars......